Nicotinamide Riboside (NR)


Pyridine nucleoside NAD+ precursor and vitamin B3 vitamer

A naturally occurring pyridine nucleoside form of vitamin B3 that serves as a direct precursor to nicotinamide adenine dinucleotide (NAD+) through the nicotinamide riboside kinase pathway, distinguished from other NAD+ precursors by direct cellular uptake, absence of flushing, and a growing clinical evidence base in aging, neurodegeneration, and cardiovascular function.

Abstract

Nicotinamide riboside (NR) is a pyridine nucleoside form of vitamin B3 and a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), the essential redox cofactor and sirtuin/PARP cosubstrate whose decline with aging is implicated in mitochondrial dysfunction, genomic instability, neurodegeneration, and metabolic disease. First identified as an NAD+ precursor in yeast by Bieganowski and Brenner in 2004 [1], NR is phosphorylated by the conserved nicotinamide riboside kinases NRK1 and NRK2 to nicotinamide mononucleotide (NMN), which is subsequently adenylylated by nicotinamide mononucleotide adenylyltransferases (NMNATs) to yield NAD+. This two-step pathway is independent of the Preiss-Handler and de novo biosynthetic routes and constitutes a distinct salvage mechanism for NAD+ repletion.

The compound attracted broad scientific attention following the 2012 demonstration by Canto, Houtkooper, Auwerx, and colleagues that dietary NR supplementation in mice activates SIRT1 and SIRT3, enhances mitochondrial oxidative metabolism, and protects against high-fat-diet-induced obesity and metabolic dysfunction [2]. Subsequent preclinical work established NR-mediated NAD+ repletion as protective in mouse models of dilated cardiomyopathy [3], noise-induced hearing loss, Alzheimer-like neurodegeneration, Parkinson disease [4], hepatic steatosis, muscular dystrophy, and age-related stem cell decline. In each case, the proposed mechanism centers on restoration of NAD+-dependent sirtuin and poly(ADP-ribose) polymerase activity in metabolically stressed tissues.

The Elhassan et al. (2019) study demonstrated that NR augments the aged human skeletal muscle NAD+ metabolome and induces anti-inflammatory transcriptomic signatures [8].

Despite consistent pharmacodynamic evidence that oral NR elevates NAD+ in blood, muscle, and brain, clinically meaningful efficacy endpoints have proven elusive in most completed trials. NR has not demonstrated significant effects on insulin sensitivity, whole-body glucose metabolism, or skeletal muscle mitochondrial bioenergetics in randomized controlled trials in obese or older adults [10, 11]. Cognitive endpoints have not reached significance in trials of mild cognitive impairment [12]. The compound is therefore positioned as a well-tolerated NAD+ repletion agent with strong preclinical rationale, consistent pharmacodynamic activity, and an incomplete clinical efficacy record that awaits adequately powered Phase 2 and Phase 3 trials in disease-specific populations.

Nicotinamide riboside chloride is marketed as the dietary supplement Niagen (ChromaDex/Niagen Bioscience) and has received Generally Recognized as Safe (GRAS) status from the United States Food and Drug Administration for use as a vitamin B3 source in foods [13], as well as two successful New Dietary Ingredient notifications for use in dietary supplements. The compound is not approved as a drug for any indication. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph